Rome Therapeutics raises $77m for junk DNA-targeting drugsStartup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which Share XRome Therapeutics raises $77m for junk DNA-targeting drugshttps://pharmaphorum.com/news/rome-therapeutics-raises-77m-for-junk-dna-targeting-drugs/
Novartis’ transplant drug hope iscalimab flunks mid-stage trialNovartis hopes of improving on tacrolimus as the standard drug for preventing organ rejection in transplant patients have Share XNovartis’ transplant drug hope iscalimab flunks mid-stage trialhttps://pharmaphorum.com/news/novartis-transplant-drug-hope-iscalimab-flunks-mid-stage-trial/
Lilly taps Lycia for protein degrader tech in $1.6bn dealEli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal Share XLilly taps Lycia for protein degrader tech in $1.6bn dealhttps://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/
With Alzheimer’s market opening up, Lilly forms neuroscience unitEli Lilly is one of the front runners in the bid to follow Biogen and Eisai onto the Share XWith Alzheimer’s market opening up, Lilly forms neuroscience unithttps://pharmaphorum.com/news/lilly-forms-neuroscience-unit/
Bayer bolsters R&D platform with $2bn Vividion takeoverBayer headlined its second-quarter results this morning by unveiling a deal to buy Vividion Therapeutics, saying it will Share XBayer bolsters R&D platform with $2bn Vividion takeoverhttps://pharmaphorum.com/news/bayer-bolsters-rd-platform-with-2bn-vividion-takeover/
Sanofi swoops on partner Translate, buying the mRNA firm for $3.2bnSanofi has been forging ever-closer ties with its mRNA partner Translate Bio since the two started working together Share XSanofi swoops on partner Translate, buying the mRNA firm for $3.2bnhttps://pharmaphorum.com/news/sanofi-swoops-on-partner-translate-buying-the-mrna-firm-for-3-2bn/
Final hurdle falls as UK backs AZ’s $39bn takeover of AlexionThe UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a Share XFinal hurdle falls as UK backs AZ’s $39bn takeover of Alexionhttps://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/
Merck makes another bioelectronics play, partnering with InnerviaMerck KGaA has forged a second partnership in the bioelectronics category in two weeks, teaming up with Innervia Share XMerck makes another bioelectronics play, partnering with Innerviahttps://pharmaphorum.com/news/merck-makes-another-bioelectronics-play-partnering-innervia/
COVID-19 neutralising antibody tests – an integrated approachNina Garrett, R&D director at Abingdon Health discusses the key role antibody testing is playing in the pandemic Share XCOVID-19 neutralising antibody tests – an integrated approachhttps://pharmaphorum.com/views-and-analysis/covid-19-antibody-tests-integrated-approach/
